Clinically approved HIF-PHIs modulate redox metabolism, cell growth, and angiogenesis independent of HIF-1α/HIF-2α

HIF-prolyl hydroxylase inhibitors are used to treat anemia in chronic kidney disease. These drugs stabilize hypoxia-inducible factors HIF-1α and HIF-2α, which activate erythropoiesis and iron metabolism pathways. Clinically approved HIF-PHIs including roxadustat and molidustat exhibit distinct molec...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Daniela Mennerich, Fawzi Khoder-Agha, Mustafa Beter, Elitsa Y. Dimova, Seppo Ylä-Herttuala, Thomas Kietzmann
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2026-07-01
Serie:	Redox Biology
Soggetti:	HIF-1α HIF-2α Roxadustat Molidustat RNAseq
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2213231726002041
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!